PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced the launch of its NeoBase™ 2 non-derivatized MSMS Kit, which obtained CE mark approval allowing distribution in Europe . This new in-vitro diagnostic (IVD) kit is intended for the semi-quantitative measurement and evaluation of amino acid, succinylacetone, free carnitine, acylcarnitine, nucleoside and lysophospholipid concentrations. The kit analyzes newborn heel prick blood samples dried on filter paper and is used with a tandem mass spectrometer.
The NeoBase2 MSMS kit can test for up to 57 analytes, including markers for screening of X-linked adrenoleukodystrophy (X-ALD), the most common peroxisomal disorder. It can also screen for adenosine deaminase severe combined immunodeficiency (ADA-SCID), which is caused by a deficiency of the enzyme ADA and is the second most common SCID.
The NeoBase2 MSMS kit enables labs to use a simple three-step assay workflow to screen for more disorders in less time from a single dried blood spot punch. PerkinElmer’s optional MSMS Workstation software, which includes database functionality, helps labs effectively store, manage, review and report results.
“As the industry leader in mass spectrometry-based newborn screening, we continue to evolve our technologies to meet the needs of laboratories worldwide, especially as more countries mandate certain metabolic tests such as those for SCIDs and peroxisomal disorders,” said Linh Hoang MD, PhD, Vice President, Neonatal Screening, PerkinElmer. “As these labs face pressure to screen for more disorders in less time and with limited resources, they are seeking advanced technology to expand their MSMS testing capabilities.”
PerkinElmer currently serves customers in more than 100 countries worldwide. Its customers have screened more than 600 million babies throughout the world for life- threatening diseases: screening 39 million babies annually around the world, helping to save more than 70 babies per day (one baby every 20 minutes).